Clin2
NCT06795646Possibly a fitNot yet recruiting

Fatty liver disease study using liver biopsy

Metabolic Dysfunction Associated Steatotic Liver DiseaseMetabolic Dysfunction-associated Steatohepatitis (MASH)

Part of Digestive system, Hormones & metabolism clinical trials.

This study classifies fatty liver disease (MAFLD) by examining liver tissue samples. It aims to better understand how metabolic risk factors like high blood sugar, high blood pressure, or excess weight relate to the liver's condition.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
2,000 people
Ages
Any age
Study type
Observational

Who can take part

  • You have fatty liver confirmed by ultrasound.
  • You have at least one metabolic risk factor, such as being overweight, having high blood sugar, high triglycerides, low HDL cholesterol, or high blood pressure.
  • You are willing to have a liver biopsy to check your liver tissue.
  • You do not drink alcohol heavily (more than 30 grams/day for men, 20 grams/day for women).
  • You do not have hepatitis B or C, a history of cancer, heart disease, chronic kidney disease, severe liver cirrhosis, or a liver transplant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07188220Recruiting
Understanding patient views on fatty liver disease study

This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.

Barcelona
NCT07313007Recruiting
Gut bacteria chemicals in fatty liver disease

This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.

Pierre-Bénite
NCT06836609Recruiting· Phase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)

This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.

Chandler, Arizona
NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease

This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.

Chandler, Arizona
NCT06514300Enrolling by invitation
Study of muscle fat in fatty liver disease

This study looks at how fat in the muscles may affect liver disease in people with fatty liver and related conditions like obesity or diabetes. It aims to better understand the connection between muscle fat and liver health.

Brussels
NCT07122700Recruiting
Better tests for fatty liver disease in people with metabolic issues

This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.

Miami, Florida

Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.